Rising prevalence of heart diseases
The growing number of people diagnosed with heart disease is the major driver of the anti-coagulants market. According to the World Health Organization (WHO), 17.9 million people die each year due to cardiovascular diseases (CVDs), an estimated 31% of all deaths worldwide. Increasing consumption of tobacco, unhealthy diet, and physical inactivity are raising the risk of heart attacks and strokes. According to the Centre for Disease Control and Prevention, heart disease has been the major cause of death in the United States in which coronary heart disease is the most common type of heart disease. The rising obese population is one major cause of heart attack. According to the WHO, the worldwide prevalence of obesity nearly tripled between 1975 and 2016. All these factors are driving the demand anticipated to propel the demand for these medicines across the globe as doctors are focusing on a combination of risk factors for these diseases, implementing medical screening for individuals at risk, and then providing effective treatment to prevent disability and death while improving quality of life. Also, these medicines are suitable for patients who suffered a heart attack as these medicines lower the risks of another heart attack. Furthermore, a growing number of heart attacks is propelling the demand for these medicines. For instance, as per the U.S. Department of Health and Human Services, every year 725,000 people have a heart attack out of which approximately 30% are those people who have already had a heart attack. Thereby, positively impacting the anti-coagulants market growth during the forecast period and beyond.
Deep Vein Thrombosis to hold a notable share
On the basis of application, the global anticoagulants market has been segmented into atrial fibrillation, heart attacks, deep vein thrombosis, pulmonary embolism, and others. The deep vein thrombosis segment is anticipated to hold a significant share owing to its high incidence in developing countries. According to the U.S Department of Health and Human Services, the prevalence of deep vein thrombosis accounts for 2 per 1000 people each year in the United States.
Furthermore, the anti-coagulants market for atrial fibrillation is anticipated to show a notable growth over the forecast period owing to the fact that this disease increases the risks of heart attacks, stroke, and heart failure due to the formation of blood clots. Also, the growing prevalence of this disease across the globe is also a key factor that is expected to bolster the demand for anti-coagulants and thereby positively impacting the market growth in the coming years.
North America to hold a noteworthy share
Geographically, the global anticoagulants market has been segmented into North America, South America, Europe, the Middle East and Africa, and the Asia Pacific. These regions have been further segmented into countries that hold a significant share in the market. North America is expected to hold a significantly large share in this market. The growth in this region is majorly attributed to state-of-the-art healthcare infrastructure which is expected to continue improving as industry players continue to funnel in huge investments in this sector in these regions. The market in the Asia Pacific is being driven by supportive initiatives by some governments in order to make expensive healthcare services accessible for people of all income groups.
Competitive Insights
Prominent key market players in the anti-coagulants market include Pfizer Inc., Bayer AG, Johnson & Johnson Services, Inc., Sanofi S.A., GlaxoSmithKline plc, and Portola Pharmaceuticals, Inc., among others. These companies hold a noteworthy share in the market on account of their good brand image and product offerings.
Major players in the anti-coagulants market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last two years.
| Report Metric | Details |
| Market size value in 2019 | US$26.293 billion |
| Growth Rate | CAGR of during the forecast period |
| Base year | 2019 |
| Forecast period | 2020–2025 |
| Forecast Unit (Value) | USD Billion |
| Segments covered | Drug Class, Application, And Geography |
| Regions covered | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies covered | Aspen Holdings, Bayer AG, Portola Pharmaceuticals, Inc., Sanofi S.A, Boehringer Ingelheim International GmbH, DAIICHI SANKYO COMPANY, LIMITED, GlaxoSmithKline plc, Pfizer Inc., Johnson & Johnson Services, Inc., Bristol Myers Squibb |
| Customization scope | Free report customization with purchase |
Segmentation
Frequently Asked Questions (FAQs)
Aspen Holdings
Bayer AG
Portola Pharmaceuticals, Inc.
Sanofi S.A
Boehringer Ingelheim International GmbH
DAIICHI SANKYO COMPANY, LIMITED
GlaxoSmithKline plc
Pfizer Inc.
Johnson & Johnson Services, Inc.
Bristol Myers Squibb
All our studies come with 2 months of analyst support.
We are in compliance with the global privacy laws.